Eli Lilly and Company (NYSE:LLY) does about 3.26M shares in volume on a normal day but saw 4430706 shares change hands in Monday trading. The company now has a market cap of 143.50B USD and an enterprise value of about $156.43B. Its current market price is $148.39, marking an increase of 0.71% compared to the previous close of $147.34. The 52 week high reached by this stock is $170.75 whilst the lowest price level in 52 weeks is $101.36. The script in recent trading has seen the stock touch a high of $148.795 and a low of $147.03.
Eli Lilly and Company (LLY) has a 20-day trading average at $151.12 and the current price is -13.10% off the 52-week high compared with 46.40% distance from its 52-week low. The 50-day simple moving average of the closing price is $157.86 and its 200-day simple moving average is $144.24. If we look at the stock’s price movements over the week, volatility stands at 1.35%, which increases to 1.66% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 36.93 to suggest the stock is neutral.
The consensus objective for the share price is $165.07, suggesting that the stock has a potential upside of 10.1% over the period.
FactSet Research has provided data showing that 15 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 8 analysts have rated it as a buy and 7 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 16, 2020 when Guggenheim upgraded the stock to “Buy” and issued a price target of . UBS downgraded the stock to “Neutral” from Buy on April 21, 2020 at a price target of $157-$158. Morgan Stanley downgraded its price target at $148.
The current price level is -1.95%, -6.14%, and 3.01% away from its SMA20, SMA50, and SMA200 respectively, with the LLY price moving above the 50-day SMA on August 31. Eli Lilly and Company (LLY) stock is down -0.76% over the week and -1.26% over the past month. Its price is 12.90% year-to-date and 31.35% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of $1.89 above consensus estimates by $0.33. The company’s next earnings report is expected on 10/27/2020, with forecasts estimating quarterly EPS at $1.72 and $7.21 for whole year. LLY’s earnings per share are forecast to grow by 19.40% this year and 10.80% over next year. Expected sales for next quarter are $6.54 billion, which analysts say will come at $23.89 billion for the current fiscal year and next year at $25.94 billion. In addition, estimates put the company’s current quarterly revenue at an average of $5.91 billion.
Its 12-month price target is $175.00. To reach the target analysts have set, the stock logically needs to grow 10.1 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $148.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $190.00.
Outstanding shares total 907.20M with insiders holding 0.15% of the shares and institutional holders owning 79.61% of the company’s common stock. The company has a return on investment of 24.60% and return on equity of 170.70%. The price to earnings ratio (P/E ratio) amounts to 24.14 while the forward price to earnings ratio is 18.56. The beta has a value of 0.19. Price to book ratio is 32.90 and price to sales ratio is 6.25.
According to a U.S. Securities and Exchange Commission filing, Vanguard Total Stock Market Index has reduced its position in Eli Lilly and Company (LLY) to 24,460,210 shares, mirroring a recent drop by -0.32%. Vanguard Total Stock Market Index dumped 77372.0 shares of Eli Lilly and Company common stock bringing its total worth to about $3.68 billion at the end of recent close, SEC documents show. Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by Vanguard PRIMECAP Fund, which sold off -0.73 million shares to end up with 21,764,208 shares worth $3.27 billion. Vanguard 500 Index Fund cut their holdings by -0.60% in the company over the course of the most recent quarter. It now holds a 1.82% position in Eli Lilly and Company thanks to 17.37 million shares amounting to $2.61 billion.